Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
01/12/2026 07:00 AM • Apellis Pharmaceuticals reported preliminary full-year 2025 U.S. net product revenues of $689 million, driven by strong performance from SYFOVRE (geographic atrophy treatment) at $587 million and EMPAVELI (kidney disease treatment) at $102 million. SYFOVRE achieved 60% market share with 17% year-over-year injection growth, while EMPAVELI reached over 5% market penetration in its target indications within five months of launch. The company maintains approximately $466 million in cash and expects to reach profitability through product revenues.
APLS - Strong commercial execution with $689M in 2025 revenues, SYFOVRE achieving 60% market leadership with 17% YoY growth, EMPAVELI exceeding 5% market penetration in just 5 months post-launch, rapid payer uptake at 95%, positive Phase 3 data published in NEJM, pipeline expansion into additional indications (FSGS, DGF), and sufficient cash position ($466M) to fund operations to profitability.
Investing.com • Ali Merchant